Perceptive Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Perceptive Advisors’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-186,662	Closed	-$10.3M	–	106
2024 Q4	$10.3M	Sell	186,662 -1,109,754	-86%	-$50.4M	0.28%	59
2024 Q3	$42.6M	Hold	1,296,416	–	–	0.9%	32
2024 Q2	$35.2M	Hold	1,296,416	–	–	0.85%	34
2024 Q1	$47.1M	Hold	1,296,416	–	–	0.82%	42
2023 Q4	$26.3M	Hold	1,296,416	–	–	0.59%	46
2023 Q3	$23M	Hold	1,296,416	–	–	0.77%	37
2023 Q2	$23.4M	Hold	1,296,416	–	–	0.68%	44
2023 Q1	$16.3M	Hold	1,296,416	–	–	0.48%	49
2022 Q4	$19M	Hold	1,296,416	–	–	0.53%	45
2022 Q3	$22.2M	Hold	1,296,416	–	–	0.64%	41
2022 Q2	$18.9M	Hold	1,296,416	–	–	0.59%	42
2022 Q1	$21.8M	Hold	1,296,416	–	–	0.44%	56
2021 Q4	$29.2M	Hold	1,296,416	–	–	0.45%	53
2021 Q3	$27.9M	Hold	1,296,416	–	–	0.41%	60
2021 Q2	$37.6M	Hold	1,296,416	–	–	0.49%	51
2021 Q1	$41.1M	Hold	1,296,416	–	–	0.52%	48
2020 Q4	$53.6M	Buy	+1,296,416	New	+$36.9M	0.58%	43

Other funds holding TARS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Perceptive Advisors's TARS Position: Q1 2025 in Review

Perceptive Advisors sold out of Tarsus Pharmaceuticals (TARS) in Q1 2025, closing a stake of 186,662 shares — an estimated $10.3M sold.

Perceptive Advisors first reported a position in TARS in Q4 2020 and held it in 17 quarters. The position peaked at $53.6M in Q4 2020. 194 funds tracked by Wall St. Rank hold TARS as of Q1 2025.

Perceptive Advisors reported no remaining Tarsus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Perceptive Advisors sold 186,662 Tarsus Pharmaceuticals shares in Q1 2025, an estimated $10.3M.
Perceptive Advisors first reported a position in Tarsus Pharmaceuticals in Q4 2020 and held it in 17 quarters.
Perceptive Advisors's Tarsus Pharmaceuticals position peaked at $53.6M in Q4 2020.
194 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2025.

Based on Perceptive Advisors's 13F filing for Q1 2025, filed 15 May 2025.